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ABSTRACT
Endogenous retroviruses (ERVs) are an inherited
part of the eukaryotic genomes, and represent
 400000 loci in the human genome. Human
endogenous retroviruses (HERVs) can be divided
into distinct families, composed of phylogenetically
related but structurally heterogeneous elements.
The majority of HERVs are silent in most physio-
logical contexts, whereas a significant expression
is observed in pathological contexts, such as
cancers. Owing to their repetitive nature, few of
the active HERV elements have been accurately
identified. In addition, there are no criteria defining
the active promoters among HERV long-terminal
repeats (LTRs). Hence, it is difficult to understand
the HERV (de)regulation mechanisms and their
implication on the physiopathology of the host.
We developed a microarray to specifically detect
the LTR-containing transcripts from the HERV-H,
HERV-E, HERV-W and HERV-K(HML-2) families.
HERV transcriptome was analyzed in the placenta
and seven normal/tumoral match-pair samples.
We identified six HERV-W loci overexpressed in
testicular cancer, including a usually placenta-
restricted transcript of ERVWE1. For each locus,
specific overexpression was confirmed by quantita-
tive RT-PCR, and comparison of the activity of U3
versus U5 regions suggested a U3-promoted tran-
scription coupled with 50R initiation. The analysis of
DNA from tumoral versus normal tissue revealed
that hypomethylation of U3 promoters in tumors is
a prerequisite for their activation.
INTRODUCTION
Integral genome sequencing data from various species
have highlighted the signiﬁcant numbers of endogenous
retroviral elements contained within the cellular
genomes. In humans, retrovirus-like elements represent
 8% of the euchromatin (1). There are at least 31
families of human endogenous retroviruses (HERVs),
each derived as a result of independent infections of the
germline by an infectious virus during the evolution of the
human lineage. Each family encompasses tens to thou-
sands of loci (2), essentially resulting from reinfection by
replication-competent elements and intracellular retro-
transposition of the transcriptionally active copies.
All contemporary copies are found to be defective for
viral replication owing to genetic drift, and are conse-
quently transmitted in a Mendelian fashion. HERVs
were initially considered as DNA parasites, but are now
suggested to contribute to biological activities. For
example, the Syncytin-1 envelope glycoprotein, encoded
by the ERVWE1 locus, which is a full-length proviral
member of the HERV-W family, is thought to contribute
to human placentation (3–5), autoimmunity (6) and
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terminal repeats (LTRs), whose original function is
retroviral-expression control, may provide transcriptional
regulatory elements for cellular genes consisting in
promoter (10), enhancer (11), antisense transcripts
negative modulators (12) or polyadenylation signal func-
tions (13). Thus, HERV proteins and LTRs appear to be
potential contributors to both human physiology and
pathology.
Nevertheless, the vast majority of the data reﬂecting
HERV behavior mainly rely on the evidence of trans-
criptional activity. Male and female reproductive tissues
as well as embryonic tissues such as the placenta are
the major sites of HERV expression. This suggests:
(i) a hormone-dependent relationship between HERV
and reproductive tract [reviewed in ref. (14)] and (ii) that
at least some LTRs are hypomethylated in these tissues,
as recently demonstrated for the ERVWE1 locus
(Syncytin-1) expressed in the placenta (15,16), and
several HERV-E LTRs that function as alternative gene
promoter in the placenta (17). In somatic cells, HERVs are
globally silent. This silencing is thought to be the result of
the methylation of the LTRs (50LTR, 30LTR, or solo
LTR) that contain the regulatory elements including
the retroviral promoter in the LTR U3-subregion.
Conversely, expression of HERV has been recurrently
observed during cellular transformation processes in
both cell culture and in vivo. Thus, approaches for
analyzing the activity of HERVs may help to elucidate
transcriptional regulation mechanisms, address physio-
pathological functions and eventually prove useful for
diagnosis and therapy.
On the basis of functional hypotheses associated with
candidate loci, the majority of HERV quantitative expres-
sion studies are based on RT-PCR (18–22). Global
methods were also developed, essentially based on the
relative conservation of the pol genes, a process known
as pan-retrovirus ampliﬁcation. For example, HERV-
taxon-speciﬁc real-time RT-PCR assays using degenerate
primers, was design to quantify the RNA expression of
some gammaretroviral HERV families (23). Alternatively,
PCR ampliﬁcation using relatively complex degenerate
primer mixtures, combined with low-density microarrays,
were developed to detect and identify the expression of
HERV families (24,25). Although these strategies aim to
analyze the overall transcription of each family, each
associated method is a compromise between quantitation
and exhaustiveness, and it thus appears that none of
the existing methods are exhaustive (26). Moreover, as
designed, these methods do not permit to follow the
expression of each locus within each family.
Thus, several global approaches were developed to try
to analyze the expression of each individual locus. The
ﬁrst one, called ‘digital expression’, compared human
EST data with prototypes loci of four families and
showed the trends concerning family tropism of the
expression, but failed to positively assign the locus to
the EST (27). An improvement of such a method was
recently published, based on HML-2 analysis (28). A
second approach, based on the utilization of PCR with
two primer pairs targeting gag and env regions of the
HML-2 family and subsequent cloning and sequencing,
detected the original transcriptionally active proviruses,
but strictly depended on the primer design and associated
putative bias (29,30). Although informative, these two
methods cannot provide any information related to
autonomous (U3 driven) versus non-autonomous (e.g.
readthrough) expression of HERVs. Moreover, as 85%
of HERV sequences consist of solitary LTR (1), namely
without gag, pol,o renv internal sequences, a major part of
the HERV transcriptome remains hidden. The recently
described genome repeat expression monitoring (GREM)
technique, terminating at the cloning and sequencing
steps, allowed identifying HML-2 human-speciﬁc
solitary LTRs acting in vivo as promoters (31,32). In this
study, we developed a high-density microarray to detect
HERV transcriptional activities in a locus-speciﬁc way.
More particularly, independent probesets for the U3 and
U5 regions of every HERV LTR were designed from
four HERV families [HERV-K(HML-2), HERV-W,
HERV-H, HERV-E]. Additional groups of probesets
were dedicated to the detection of the 16 known env
genes, some env-related splice transcripts and putative
gag ORFs. We used this microarray to explore the diﬀer-
ential activity of HERV loci in tumoral versus normal
RNA pairs from diﬀerent tumor types and in the
placenta. We found a speciﬁc up-regulation of a cluster
of HERV-W U5 probesets in the tumoral testis (TT).
Detailed analysis of the probesets provided additional
information relative to alternative splicing and LTR
self-activation, which in turn, resulted in a hypothesis
concerning an epigenetic control of these loci. Both
the levels of control were experimentally addressed on
several patient samples.
MATERIALS AND METHODS
RNA and DNA samples
RNA samples, namely breast, colon, lung, ovary,
prostate, testis and uterus First_Choice Human Tumor/
Normal Adjacent Tissue RNA and normal placenta
First_Choice Human Tissue RNA were purchased from
Ambion (Austin, TX, USA). An RNA and DNA pair
sample of human testis Tumoral/Normal Adjacent
Tissue was purchased from Clinisciences/Biochain.
Constitution of HERV genomic sequence library
First, GenBank sequences (release 128) containing
homologs for the families HERV-K(HML-2), HERV-W,
HERV-H and HERV-E were identiﬁed by Blast procedure
with default parameters (33). The accession numbers
for the full-length proviral sequences used as queries
are presented in Table 1. Subsequently, a screening of
the identiﬁed GenBank sequences containing HERVs
was performed using RepeatMasker (Smit, AFA and
Green, P RepeatMasker at http://repeatmasker.genome
.washington.edu/cgi-bin/RM2_req.pl) at a 20% diver-
gence threshold with a library containing prototype
HERV proviruses cut out into functional parts (LTR,
gag, pol, env). Finally, the resulting sequences were col-
lected and their structures were annotated.
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For each HERV family, probes were designed using the
criteria of sequence uniqueness among the genomic
sequence collection of the whole concerned HERV
family. All potential 25-mer sequences were generated
from the targeted regions. All the 25-mers were then
compared with the others to identify those occurring
uniquely. For each functional domain, a probeset
comprising unique sequences was picked out to ensure a
homogeneous spread over the targeted region. Thus, any
solo or proviral LTR may consist of two probesets, one
for the U3 region and one for the U5 region. Therefore,
for a full-length provirus, the maximum number of
probesets was four, i.e. targeting independently U3
50LTR, U5 50LTR, U3 30LTR and U5 30LTR. It is essen-
tial to note that, for a given provirus, divergence occurring
between 50 and 30 LTRs since the proviral integration
event made it possible to select distinct probes for the 50
and 30LTRs sub regions. In fact, owing to the uniqueness
ﬁlter, some LTR or LTR subregions were not represented
by any probe. Additionally, probesets for the 16 known
HERV full-length envelope genes, envH 1–3, envK 1–6,
envT, envW, envFRD, envR, envR(b), and envF(c) 1 and
2 [Table 1; (18)] were built. In addition to the envW_at
probeset detecting the ERVWE1 env region, sp.ervwe1_at,
a probeset speciﬁc for ERVWE1/Syncytin-1 mRNA was
designed, consisting of probes located at the env splice
junction (34) and at the ERVWE1 signature (35).
Likewise, probesets for the HERV-K(HML-2) np9 and
cORF/REC encoding spliced mRNA were built using
type 1 HERV-K101 (AF164609) and type 2
HERV-K(HML-2.HOM) (AC072054) proviral copies as
queries, respectively. The probes for np9 and cORF
mRNA were located at the splice junction excluding the
env region (36,37). Finally, the probesets were designed
for ﬁve putative full-length gag HERV-K(HML-2)
ORFs (2001nt) identiﬁed in the HERV genomic
sequence library. Thus, a total of 5100 HERV probesets
were generated.
In addition to the HERV probes, the standard
Aﬀymetrix control probes for unbiased ampliﬁcation (50
and 30 GAPDH and HSA probesets) and hybridization
quality (bioB, bioC, bioD and cre probesets) were
included in the microarray. MM mismatch standard
Aﬀymetrix control probes, including one central mis-
match, were not included because of the probable
frequent existence of the corresponding HERV paralo-
gous element, and also because it was shown that such
controls could be ineﬃcient (38). A set of dedicated
control probes containing two or three transversions
were designed to evaluate intrafamily putative
Table 1. Reference sequences used to constitute the HERV genomic library and microrarray probesets
Family Reference sequence Probeset
Designation Genomic position Nomenclature
HERV-K(HML-2) HERV-K(C7)
a,b ( ) chr7: 4588583–4598054 H2’number’.’region’
envK1
c ( ) chr12: 57008430–57010526 envk1
envK2
c (+) chr7: 4589506–4591605 envk2
envK3
c ( ) chr19: 32821333–32824298 envk3
envK4
c ( ) chr6: 78484295–78486392 envk4
envK5
c ( ) chr19: 32821286–32823386 envk5
envK6
c ( ) chr8: 7343729–7345828 envk6
np9
d (+) chr22: 17312661–17314316 sp.np9
cORF/REC
d (+) chr7: 4589627–4591360 sp.corf
HERV-W ERVWE1
a ( ) chr7: 91935220–91945441 HW’number’.’region’
envW
c ( ) chr7: 91936015–91937571 envw
ERVWE1/Syncytin-1
d ( ) chr7: 91936164–91945269 sp.ervwe1
HERV-H HERV-H19
a (+) chr2: 166272309–166280954 HH’number’.’region’
envH1
c ( ) chr2: 166272946–166274699 envh1
envH2
c ( ) chr3: 168023715–168025406 envh2
envH3
c (+) chr2: 155436978–155438645 envh3
HERV-E HERV-E4.1
a ( ) chr19: 20721466–20730278 HE’number’.’region’
HERV-T envT
c (+) chr19: 20341241–20343121 envt
HERV-FRD envFRD
c (+) chr6: 11211913–11213529 envfrd
ERV3/HERV-R envR
c (+) chr7: 64088729–64097156 envr
HERV-R(b) envR(b)
c (+) chr3: 16786814–16788359 envr(b)
HERV-F(c) envF(c)1
c (+) chrX: 96988918–96990890 envf(c)1
envF(c)2
c ( ) chr7: 152737681–152739128 envf(c)2
Family aﬃliation of the reference sequences is indicated in the ﬁrst column. The reference sequences were used to generate
aLTR probesets.
bgag probesets.
cenv probesets.
dprobesets at the splice junctions.
The position in accession number correspond to the whole HERV provirus in a and b, and to the probeset area in c and d.
‘Number’ in probeset nomenclature refers to the locus accession number in the HERV library. ‘Region’ in probeset nomen-
clature is ‘L5.’s ‘L3.’ or ‘LS.’ for 50LTRs, 30LTRs or soloLTRs, respectively, followed by ‘U3’ or ‘U5’ in function of the region
targetted in the LTR and ‘GAG’ for HERV-K(HML-2) putative full-length ORFs.
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Target ampliﬁcation/labeling and microarray
hybridization
cDNA synthesis and transcriptional ampliﬁcation were
performed using 400ng of RNA following the Whole
Transcripts Ampliﬁcation protocol (WTA, Aﬀymetrix).
Brieﬂy, dsDNA synthesis was performed using random
primers with a T7 promoter tail (T7-N6) and reverse
transcriptase/RNAseH mix. An antisense RNA (cRNA)
was produced by adding T7 polymerase. The cRNA
ampliﬁcation products were cleaned on RNeasy columns
(RNeasy mini kit, Qiagen) and used as template for
dsDNA synthesis. Ampliﬁed dsDNA products were
puriﬁed using the QIAquick puriﬁcation kit (Qiagen)
and their quality was assessed with a Bioanalyzer capillary
electrophoresis device (Agilent, Palo Alto, USA). Sixteen
micrograms of puriﬁed dsDNA were fragmented into 50–
200bp fragments using DNAseI treatment and labeled at
the 30OH termini by introducing biotinylated dNTPs using
terminal transferase. The 16-mg fragmented dsDNA were
mixed with standard hybridization controls and oligo B2
following the recommendations of the supplier. This
hybridization cocktail was heat-denatured at 90 C for
10min, incubated at 50 C for 5min and centrifuged at
16000g for 2min to pellet the residual salts. At the same
time, the HERV GeneChip microarray was prehybridized
using 200ml of hybridization buﬀer in an oven at 60 C,
under agitation at 60r.p.m. for at least 10min. The
hybridization buﬀer was then replaced by the denatured
hybridization cocktail containing labeled targets.
Hybridization was performed at 50 C for 16h in a hybrid-
ization oven with constant rotation (60r.p.m.). Washing
and staining were carried out according to the protocol
supplied by the manufacturer, using a ﬂuidic station
(GeneChip ﬂuidic station 450, Aﬀymetrix). The probe
arrays were scanned using a ﬂuorometric scanner
(GeneChip scanner, Aﬀymetrix). The experiments were
performed in triplicate, that is three independent ampliﬁ-
cations and hybridizations were performed for each
clinical sample.
Expression analysis
Expression analysis was performed using R statistical
software (39) and packages from the Bioconductor
project (40).
The quality of the microarrays was assessed with
standard Aﬀymetrix quality controls extracted from
GCOS report (GeneChip Expression Analysis Data
Analysis Fundamentals, Aﬀymetrix). All the microarrays
fulﬁlled the criteria. The images produced by the scanner
of the log-transformed intensities were visually inspected,
and distribution homogeneity of the array intensities
was also checked with boxplots and histograms of
log2 intensities.
Robust multi-array averaging (RMA) method (41) was
used for background correction (RMA), normalization
(quantiles method) and summarization (median polish
method) of the microarray data.
The expression data were ﬁltered by removing the
low-expressed probesets. The maximum expression of
each probeset across the arrays was computed. Probesets
with a maximum expression lower than the median
(i.e. 70) of the distribution of maximum values were con-
sidered to be low-expressed and were removed.
Identiﬁcation of diﬀerentially expressed probesets
among the samples was performed with a multiclass sig-
niﬁcance analysis of microarrays (SAM) based on a ﬁsher
test (42). SAM provides permutation-based estimations of
the false-discovery rate (FDR) associated with the lists
of probesets for which the null hypothesis is rejected.
The null hypothesis states that ‘the intensity associated
with a probeset remains the same in all samples’. An
FDR cutoﬀ of 1% was applied (cel ﬁles are available
upon request).
Real-time RT-PCR
A set of locus-speciﬁc PCR primer pairs was obtained
using the Primer3 software, and the best primer pair
was selected using BLAT and in silico PCR at UCSC
genome browser (http://genome.ucsc.edu/cgi-bin/hgPcr)
to optimize speciﬁcity (Supplementary Table S1).
Primers targeting ERVWE1-spliced env mRNA were
designed as previously described for overlapping splice
junction (43). All the RT-PCR products were sequenced
and mapped onto the genome (UCSC genome March
2006 version 36.1) to check whether each retained
primer pair actually matched only one speciﬁc locus.
One microgram of each total RNA was reverse-
transcribed in a volume of 20ml containing 1X ﬁrst-strand
buﬀer, 0.01M of DTT, 40U of RNaseOUT, 0.5mM of
dNTP-Mix, 250ng of random primers (Promega,
Madison, USA) and 200U of SuperScriptII (Invitrogen,
Carlsbad, USA) according to the manufacturers’ recom-
mendations. Reverse-transcriptase-free reactions were
carried out to verify the absence of contaminating
genomic DNA.
The cDNA were used for real-time PCR based on
SYBR green ﬂuorescence. After 100-fold dilution, 10ml
of cDNA were mixed with 1ml of 2.5mM forward
primer, 1ml of 2.5mM reverse primer (Supplementary
Table S1), 0.5ml of water and 12.5ml of Brilliant
qPCRMaster Mix. The volume of the reaction mixture
was 25ml. PCR ampliﬁcation was carried out in eight-well
strips using an M 3005P thermal cycler (Stratagene). The
housekeeping genes (G6PD, GAPDH and HPRT) were
analyzed in the same experiment as the target transcripts.
Ampliﬁcations of cDNAs, including those of RT-minus
cDNA synthesis reactions, were performed as follows: a
10-min denaturation step at 95 C, followed by 40 or 46
cycles at 95 C for 30s, at 55 C for 1min, and at 72 C for
1min. An additional cycle at 95 C for 1min, at 60 C for
30s and at 95 C for 30min was performed at the end of
the run to establish the dissociation curves. Each sample
was analyzed at least twice to assess assay reproducibility.
Quantiﬁcation of each targeted transcript was performed
using an external standard calibration curve, designed
using serial dilutions of a reference sample. The reference
samples in the cloned PCR-ampliﬁed genomic regions
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targeting the pCR2.1 topo cloning vector, and the
ampliﬁcation products were used as templates for
calibration curves. G6PD that appeared to be the most
stable housekeeping gene between the tumoral and the
normal adjacent tissues was chosen to normalize the
experiments.
50 Rapid ampliﬁcation of cDNA ends
For the identiﬁed diﬀerentially expressed transcripts, 50
Rapid ampliﬁcation of cDNA end (RACE) was per-
formed using the SMART
TM RACE cDNA ampliﬁcation
Kit (Clontech). First-strand 50RACE cDNA synthesis was
performed on 1mg of total RNA with the 50-CDS primer,
following the manufacturer’s instructions. Ampliﬁcation
of the transcripts at the 50 end was performed on the
resulting 50-RACE-Ready cDNA, with the real-time
qRT-PCR ‘U5’ reverse primers as the gene-speciﬁc
primers (Supplementary Table S1). The recommended
TFR-gene 50-RACE control and gene-of-interest ampliﬁ-
cation control (using U5 forward and reverse primers)
were carried out in the same experiments. Reverse
primers were located maximally at  550bp downstream
from the theoretical retroviral initiation site. Therefore,
the elongation time was ﬁxed to 3min, enabling ampliﬁ-
cation of up to 4-kb fragments. The initial cycle numbers
were ﬁxed at 25, and were increased up to 30 or 35 cycles
when necessary. Alternatively, nested 50RACE was carried
out. The 50-RACE products were loaded onto a 1.2%
agarose gel, and excised and puriﬁed using NucleoSpin
Extract II Kit (Macherey Nagel). The RACE products
were then cloned using the TOPO TA cloning kit
(Invitrogen) and sequenced for 50-end characterization.
Sodium bisulﬁte modiﬁcation of the genomic DNA and
methylation analyses
The methylation status of LTR U3 region was determined
using Bisulﬁte Sequencing PCR. Bisulﬁte treatment
converts all, except the methylated (protected) cytosines,
to uracil. Uracils are further read as thymines by the poly-
merase during the PCR step. Subsequently, sequencing
allows for the identiﬁcation of methylated cytosine that
is not converted to thymidine. The genomic DNA (1mg)
from the testicular tumor and normal adjacent testicular
tissue was modiﬁed by bisulﬁte using EZ DNA
methylation kit (Zymo Research), according to the man-
ufacturer’s instructions, except for the conversion time.
The incubation time with the CT conversion reagent
(Zymo Research), was reduced to 9h, to obtain
bisulﬁte-unconversion signatures discriminating the
ampliﬁed genomic molecules without generating
false-positive unmethylated CpGs (optimizations done
in our laboratory are not presented). The DNA was
eluted in 30ml of sterile water.
PCR ampliﬁcations were performed using strand-
speciﬁc primers (Supplementary Table S2) designed to
speciﬁcally amplify the HERV of interest. The primers
for the ﬁrst and nested PCR are listed in the
Supplementary Table S2. For the ﬁrst PCR, 3mlo f
modiﬁed DNA was mixed with 0.66mM of reverse and
forward primers, 0.2mM of each dNTP, 1U of
Platinium Taq polymerase (Invitrogen), 1 of Mg-free
buﬀer (Invitrogen) and 1.5mM of MgCl2 (Invitrogen),
reaching a ﬁnal volume of 50ml. The reactions were per-
formed in an Eppendorf Thermocycler (Eppendorf).
The reaction conditions were as follows: an initial
denaturation step at 94 C for 5min, followed by 40
cycles at 94 C for 1min, at an annealing temperature
depending on the primer for 1min, at 72 C for 1min,
and a ﬁnal extension step at 72 C for 10min.
The nested PCR (if necessary) was performed with 1ml
of ﬁrst PCR products under the same mixture and ampli-
ﬁcation conditions for 30 cycles (primer and annealing
temperatures used are presented in Supplementary Table
S2). The ampliﬁcation products were puriﬁed using
Nucleospin Extract II (Machery Nagel), following
extraction on 1% agarose gel. The amplicons were
cloned using TOPO TA Cloning kits (Invitrogen).
Positive clones were selected by LacZ gene reporter
control and EcoRI restriction. The clones were then
sequenced using ABI Prism 3100 Genetic Analyzer
(Applied Biosystems). Each sequence was aligned and
compared with the in silico modiﬁed sequence to
determine the methylation status of each CpG, the rate
of conversion, and the errors in cytosine conversion,
which distinguish the molecularly independent clones.
RESULTS
Identiﬁcation of diﬀerentially expressed HERV loci by
DNA microarray and qRT-PCR validation
To investigate the HERV transcriptome in a locus-speciﬁc
manner, we developed an HERV-dedicated high-density
microarray. This microarray comprised probesets for the
U3 and the U5 regions of HERV LTRs from four
families, namely HERV-E, HERV-H, HML-2 (HERV-K
superfamily) and HERV-W (Supplementary Figure S1),
and probesets for selected HERV genes, namely gag,
env, rec and np9 genes. The control probes containing
two to three transversions were included in order to
evaluate the risk of cross-reactions of the phylogenetically
related loci. Chip validation was performed (i) by
comparing the wild-type individual probes and counter-
part control signals as well as (ii) by using a well-
documented cellular model: fusion-induced BeWo cells
that show transcriptional activation of speciﬁc HERV
loci in response to forskolin treatment. The total RNA
samples from non-induced and induced BeWo cells,
normal placenta and seven pairs of tumor and normal
adjacent tissue were analyzed on the custom HERV
microarray. The raw data were corrected for noise, and
normalized and summarized using the RMA method
(‘Materials and Methods’ section). Brieﬂy, although
signals observed for the control probes could be consid-
ered as the background currently admitted for Aﬀymetrix
technology, some exceptions showed that a risk of
cross-hybridization cannot be excluded when the diver-
gence between the two probes/loci results from two
adjacent bases and/or when hybridization signals are
extremely high (see Supplementary Data 1A). This
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of control probes in this chip version, identiﬁcation of
overexpressed loci should be conﬁrmed by qRT-PCR.
Indeed, the observed correlation between DNA chip and
qRT-PCR analyzes of HERV candidate loci in the BeWo
model indicates the potential of the chip approach to
analyze the HERV transcriptome (see Supplementary
Data 1B).
Total RNA samples from normal placenta and from
pairs of tumor and normal adjacent tissue were sub-
sequently analyzed on the custom HERV microarray.
After removal of the low expressed probesets, diﬀeren-
tially expressed probesets among the samples were
identiﬁed using the SAM method. The FDR was ﬁxed
at 1%. Owing to putative intrafamily cross-reactivity, it
should be noted that the mention of an expressed probeset
reﬂects a global family, a family subset or a single locus
reactivation. The undoubtedly tagged speciﬁc locus will be
supported either by the control probeset behavior or
qRT-PCR validation. In a ﬁrst attempt, the expression
of the 100th most signiﬁcant diﬀerentially expressed
probesets was visualized with a heatmap (Figure 1). In
addition, hierarchical clustering was performed to
generate a tree (dendrogram) that groups together
probesets with similar expression proﬁles (Figure 1).
First, this hierarchical clustering allowed us to observe
one group of HERVs principally active in the placenta,
such as ERVWE1 and ERVFRDE1 loci. The probesets
detecting the ERVWE1 provirus associated mRNAs were
localized in the 50LTR U5 region (HW28073.L5.U5_at),
env region (envW_at) and speciﬁc spliced env mRNA
(sp.ervwe1_at), in addition the probeset detecting the
ERVFRDE1 provirus associated mRNAs was localized
in the env gene region (envfrd_at). The intensity fold
change for these probesets in normal placenta, when
compared with the mean intensity in other normal
samples, is reported in Table 2. Second analyses showed
tumor-speciﬁc overexpressions of HERV probeset groups
in diﬀerent tumors. We observed the signal expression of
several probesets of HERV-H family in colorectal cancer;
a set of HERV-E probesets activated in prostate, ovary
and uterus cancers; and probesets of the HERV-W and
HML-2 families in testicular cancer. Interestingly, we
also observed a heterogeneous behavior of the HERV-E
probesets in ovary, uterus and prostate tissues, that is, 14
probesets were overexpressed in all the three tumoral
tissues, two probesets were overexpressed only in ovary
and prostate tumors, seven probesets were overexpressed
only in prostate tumor, ﬁve probesets were down-
regulated in the uterus tumor, and ﬁnally, one probeset
was highly and similarly expressed in the prostate and
ovary tissues that were normal or tumoral. Nevertheless,
an unambiguous identiﬁcation of HERV-E and HERV-H
loci was diﬃcult owing to the ineﬃcient design of the
probes within those families. Expression detected by
these probesets may result from the expression of diﬀerent
HERV-E elements. On the contrary, one probeset for the
HERV-H family, HH34532.L5.U5_at, strictly corre-
sponded to a unique locus whose overexpression in
colon cancer (Table 2) was conﬁrmed by qRT-PCR
(data not shown). Furthermore, the envH3 sequence
corresponding to an HERV-H full-length Env ORF
behaved similarly. In testicular cancer, the expression of
gag, env, cOrf and np9 regions of HML-2 loci was
evidenced directly by their dedicated probesets, although
only three loci were unambiguously identiﬁed (Table 2).
Similarly, overexpression of six HERV-W loci in the
testicular cancer was evidenced by their respective U5
LTR probesets, namely, HW28073.L5.U5_at, HW08822.
L5.U5_at, HW33438.L5.U5_at, HW38223.L5.U5_at,
HW13386.L5.U5_at and HW22795.LS.U5_at (fold
change ranging from 5.90 to 12.80; Table 2). These six
loci are localized on diﬀerent chromosomes, showing
that they do not represent a regional cluster of reactiva-
tion. In addition, they present heterogeneous structures.
Thus, these six probesets correspond to one full-length
provirus, three env-deleted proviruses, one chimeric
provirus composed of an HERV-W (50LTR-gag) and an
HERV-L (pol-30LTR) elements and one solitary LTR
(Figure 2A). Notably, the full-length provirus is the
ERVWE1 locus whose expression in testicular tumor is
also identiﬁed by the env region (envW_at) and speciﬁc
spliced env mRNA (sp.ervwe1_at) probesets.
To validate the results obtained by the microarray
experiments, the mRNA expression levels of the newly
identiﬁed HERV-W loci were analyzed by qRT-PCR in
the same normal/tumoral samples. Locus-speciﬁc primer
pairs localized in the same regions as the probesets were
used for real-time quantitative PCR. Thus, ampliﬁcation
was conducted in the LTR U5 region for HW08822.
L5.U5, HW33438.L5.U5, HW38223.L5.U5, HW13386.
L5.U5 and HW22795.LS.U5. HW28073/ERVWE1 ampli-
ﬁcation was carried out with two primer sets localized in
the env region and at the env-speciﬁc mRNA splice
junction, respectively. All the loci were overexpressed in
the testicular tumor when compared with the normal
adjacent section, with fold changes ranging from 71 for
HW22795 up to 3226 for HW33438 (Figure 2B). In
addition, an absence of diﬀerential expression in other
tumoral/normal tissues was observed. Altogether, these
results validate the microarray data for testicular-tumor-
speciﬁc reactivation of the U5 or env regions for all the six
loci.
Identiﬁcation of the splicing strategy: the particular
case of ERVWE1 locus
The envW_at and the sp.ervwe1_at probesets, used to
trace ERVWE1 proviral activity, could detect all env-
containing transcripts (8 and 3.1kb) and only the env-
encoding transcript (3.1kb), respectively (Figure 3A).
The data generated from the microarray indicated that
the locus did not present any signiﬁcant activity in the
normal testis sample, as opposed to the signiﬁcant
activity observed in placenta and TT (Figure 3B).
Nevertheless, as only one probe (overlapping splice
junction) of the sp.ervwe1_at probeset exhibited a signif-
icant intensity, which supports the env-speciﬁc splicing
strategy, these results were conﬁrmed by qRT-PCR.
To reduce putative sample bias, four testicular sample
pairs were investigated using two primer pairs
(Supplementary Table S1) that ampliﬁed the 8 and
2234 Nucleic Acids Research, 2010,Vol.38, No. 7Figure 1. HERV expression heat-map visualization. Figure shows a heat-map visualization based on the expression of the 100 most signiﬁcant
probesets for all samples and obtained by hierarchical clustering of probeset expression. The hierarchical clustering is represented by the dendrogram
on the left-hand side, and is based on the correlation distance between the probeset expression proﬁles. The color assigned to each point in the
heat-map grid is based on the level of expression (log2 scale) of one probeset (rows) in one sample (columns). Red indicates a high expression and
green indicates a low expression. Br, breast; Co, colon; Lu, lung; Ov, ovary; Pro, prostate; Ut, uterus; Te, testis; Pl, placenta; N, normal tissue; T,
tumoral tissue.
Nucleic Acids Research,2010, Vol.38, No. 7 22353.1-kb mRNAs in the env region (envW) and only the
3.1-kb mRNA (sp.ervwe1), respectively. All RT-PCR
data were normalized on G6PD, which exhibited an
average copy number among the experiments of 1000
copies per 5ng of total RNA (250 cells). A signiﬁcant
activity was evidenced in three normal testicular samples
(from 1700 to 5800 copies), except the one previously
analyzed with the microarray. Conversely, no signiﬁcant
Syncytin-1-speciﬁc spliced mRNA expression was
observed in all the normal testis samples. In all the four
TT samples, the ERVWE1 locus expression level was
found to be up-regulated (from 15000 to 52000 copies).
Moreover, Syncytin-1 mRNA production appeared to be
a common but heterogeneous attribute of TT samples
(from 242 to 2733 copies) (Figure 3C), suggesting a
change in ERVWE1 splicing strategy in the tumor.
Transcription of the reactivated HERV-W loci is
essentially autonomous
It is notable that among the 100 most diﬀerentially
expressed probesets, the U5 regions are overrepresented
when compared with the microarray composition
(Supplementary Figure S1 and Figure 1). The U3, R and
U5 juxtaposed regions of LTRs exhibit distinct putative
functions. Conventionally, in proviral 50LTR (and solo
LTRs), U3 acts as a promoter and the R-U5 region is
transcribed. In proviral 30LTR (and putatively solo
LTR), R acts as a polyadenylation signal and U3-R is
transcribed. Thus, for a complete provirus, the larger tran-
script consists of RU5–gag–pol–env–U3R. As noted in the
Materials and Methods section, divergence occurring
between 50 and 30 LTRs since the proviral integration
made it possible to select distinct probes and ampliﬁcation
primers for the 50 and 30LTRs sub regions. In line with
this, all the HERV-W loci reactivated in testicular tumor
are observed to possess full-length LTRs (50 or solo), and
only the U5 regions have diﬀerentially expressed
probesets. Associated U3 probesets targeting 50LTRs for
HW08822, HW13386 and HW38223 and included in the
microarray are poorly and not diﬀerentially expressed in
the normal and tumoral testicular samples (Figure 4A).
The divergence in microarray intensities between the U3
and U5 regions for each individual LTR could reﬂect an
autonomous (U3-mediated) activation of these loci. Such
information is not available for ERVWE1, HW22795 and
HW38223 as U3 probesets could not be designed.
We investigated the HERV-W LTRs transcription start
by 50-RACE experiments on the tumoral testicular
mRNA. The results were conclusive for one locus,
namely HW08822. The identiﬁed cap site of HW08822
Table 2. Microarray-based diﬀerential expression of the most signiﬁcant HERV probesets
a
Probesets
b Family
b Copy position
c Global analysis
d Pairwise comparaison
e
raw p-value q-value expression levels fold change
Placenta Others Placenta
HW28073.L5.U5_at HERV-W ( ) chr7: 91935211–91945442 0.00E+00 0.00E+00 38.4 393.9 10.25
envw_at HERV-W (–) chr7: 91935211–91945442 0.00E+00 0.00E+00 25 273.8 10.95
sp.ervwe1_at HERV-W (–) chr7: 91935211–91945442 0.00E+00 0.00E+00 33.2 1014.8 30.57
envfrd_at HERV–FRD (–) chr6: 11210982–11215545 1.16E–06 7.43E–06 10.7 95.4 8.92
envR_at ERV3/HERV–R (–) chr7: 64088729–64097156 6.77E–05 4.14E–05 56.9 127.8 2.25
Tumoral colon Colon N Colon T
HH34532.L5.U5_at HERV–H (+) chr1: 68624274–68630265 9.70E–07 7.39E–06 9.9 14.1 1.42
envH3_at HERV–H (+) chr2: 155436773–155438869 6.01E–06 1.54E–05 32.7 181.2 5.54
Tumoral testis Testis N Testis T
HW28073.L5.U5_at HERV–W (–) chr7: 91935211–91945442 0.00E+00 0.00E+00 29.9 202.6 6.78
envw_at HERV–W (–) chr7: 91935211–91945442 0.00E+00 0.00E+00 12.1 154.9 12.80
sp.ervwe1_at HERV–W (–) chr7: 91935211–91945442 0.00E+00 0.00E+00 21.1 268.6 12.73
HW08822.L5.U5_at HERV-W (–) chr4: 41982210–41989670 0.00E+00 0.00E+00 76.9 984 12.80
HW13386.L5.U5_at HERV–W (+) chr13: 68693758–68697469 3.88E–07 3.67E–06 54.9 428.4 7.80
HW38223.L5.U5_at HERV–W (+) chr2: 17383688–17391462 3.88E–07 3.67E–06 18.3 211.4 11.55
HW33438.L5.U5_at HERV–W (+) chr21: 27148626–27156169 3.88E–07 3.67E–06 27.1 203.9 7.52
HW22795.LS.U5_at HERV–W (+) chrX: 113026617–113027400 2.91E–06 1.33E–05 49.5 292.2 5.90
envk5_at HML-2 (–) chr5: 156018263–156019973 3.10E–06 1.33E–05 14.6 105.3 7.21
envk6_at HML-2 (–) chr8: 7343775–7351309 3.10E 06 1.33E 05 47.3 411.7 8.70
H2035746.GAG_at HML-2 (–) chr12: 57008477–57015997 3.88E 07 3.67E 06 18.4 164.6 8.95
Tumoral prostate Prostate N Prostate T
envR_at ERV3/HERV-R (–) chr7: 64088729–64097156 6.77E–05 4.14E–05 41 99 2.41
aOnly the most signiﬁcant probesets identiﬁed by global SAM analysis are presented. Probesets are classiﬁed according to the site in which the
overexpression is observed.
bThe names of the probeset and HERV family are indicated.
cThe orientation of the copy onto the DNA strand, the chromosome number, and the positions of the ﬁrst and terminal bases of the copy on the
chromosome are indicated (UCSC genome March 2006 version 36.1).
dRaw p– and q–value summarized the results of the global analysis among all the samples. The raw p–value was obtained by SAM multiclass test and
q–value was the lowest False Discovery Rate at which the probeset was considered signiﬁcant.
eFor pairwise comparison, the reference conditions are deﬁned by either the corresponding normal tissue for tumoral site of overexpression, or by all
non–placenta normal tissues for placenta. The expression levels are summarized by the median values. The degree of diﬀerential expression between
reference and overexpressed sites is expressed as fold change.
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ERVWE1 at the U3/R boundary (Figure 4B), thus con-
ﬁrming the promoter action of the U3 region in the
testicular tumor transcriptional induction. Alternatively,
using qPCR, we performed comparative assays on the
transcriptional levels of the U3 regions versus the U5
regions for the six overexpressed HERV-W loci in the
four normal/tumoral testicular sample pairs. In this
assay, an autonomous driving was reﬂected by the
U5-only transcription, and three main transcriptional
proﬁles were observed (Figure 4C).
First, we observed a clear dichotomic expression
between U3 and U5 regions for the loci HW08822,
HW13386, HW38223 and HW28073/ERVWE1. The U3
regions were not transcribed in the normal testicular
tissues and were absent or poorly expressed in the
tumoral section. On the contrary, the tumoral transcri-
ptional increase of the U5 region was conﬁrmed in all
the four sample pairs, even if activation (absolute copy
number) varied essentially as a function of the LTR. In
addition, in normal tissues, it is noticeable that the
apparent level of U5 expression of these four loci varied
among the samples, from a non-signiﬁcant expression
(<450 copies) for HW08822, HW13386 and HW38223
to a signiﬁcant expression in three samples (from 1730
to 5000 copies) for ERVWE1. Thus, transcriptional pro-
ﬁles of HW08822, HW13386, HW38223 and ERVWE1
clearly suggest a transcriptional induction through the
activation of the U3 promoter.
Second, the HW33438 locus roughly presented the same
dichotomic expression, that is, a relatively low expression
of the U3 region when compared with a high expression of
the U5 region in all the four tumoral samples. Noticeably,
an overexpression in the U3 region was observed in all the
tumoral samples within a range between 1160 and 2870.
The expression level of the U5 region, which exhibited
intersample variations similar to those described for the
loci of the ﬁrst group, varied from 3500 to 26700 copies in
the tumoral samples and from 25 to 2700 copies in the
normal counterpart.
Third, for the HW22795 locus, the situation was
much more complex. The U3–U5 dichotomy described
earlier was observed in T1 and T4 samples, that is, a
non-signiﬁcant expression of U3 region in the normal
and tumoral tissues versus U5 expression restricted to
tumoral tissues. Conversely, an exclusive U3 expression
was evidenced in T2 and T3 samples. In these samples,
U3 expression was consistently higher in the tumoral
part of the sample, but remained faint, reaching a
maximum of 347 copies.
Overall, these results suggest the existence of diﬀerent
transcriptional regulation. Nevertheless, these results
highly suggest that the testicular tumoral expression of
at least ﬁve out of the six HERV-W loci is driven by the
HERV locus-speciﬁc promoter located in the U3 region
of the LTR.
Global amount of methylation in diﬀerentially expressed
HERV-W loci and control HERVs between normal
and tumoral testicular samples
Among the possible regulatory changes that could lead to
the observed up-regulation, methylation appears to be
most frequently associated with tumoral contexts. To
validate this hypothesis, we analyzed the methylation
status of the LTR promoter part in the normal/tumoral
DNA related to the normal/tumoral testicular mRNA
sample number 4. Sequenced individual clones resulting
from the bisulﬁte-PCR-sequencing method are shown in
Figure 5. We observed a diﬀerence in the methylation
status between the tumoral and the normal DNA for all
the reactivated loci. The global amount of methylated
Figure 2. Identiﬁcation of HERV-W loci speciﬁcally up-regulated in
testicular tumor. (A) Structure and genomic position of the identiﬁed
HERV-W loci. For all the identiﬁed loci, the HERV genomic structures
are detailed: U3, R and U5 are the functional regions of the LTRs; gag,
pol and env are the proviral genes; and Denv indicates that the envelope
gene is deleted. The family type of 50 and 30 parts of the HW13386
chimeric locus are indicated. (B) Fold change between normal and
tumoral counterpart. Diﬀerential RNA expression between normal
and tumoral counterpart is indicated for each tissue (testis, uterus,
prostate, lung, breast, ovary and colon) for the six overexpressed
loci (HW08822, HW13386, HW22795, HW33438, HW38223 and
ERVWE1/Wenv). The RNA samples were similar to those used in
the microarray experiments. The qRT-PCR results were normalized
with G6PD housekeeping gene expression, which had an averaged
copy number of 1000.
Nucleic Acids Research,2010, Vol.38, No. 7 2237CpGs varied from 82 to 100% in normal DNA. In
contrast, in tumoral DNA, it varied from 0 to 30%.
Furthermore, in the tumoral DNA, 42–100% of the
sequences were completely unmethylated as illustrated in
Figure 5A, whereas none was found unmethylated in
the normal counterpart. Intriguingly, the ERVWE1 (pla-
cental) enhancer sequence, TSE, was found completely
unmethylated in half of the sequences of this normal
section, although the apparent increase in the frequency
of unmethylated sequences between normal and tumoral
tissue was observed to be consistent with the increase in
the expression of the 6 HERV-W loci. This suggests that
DNA methylation could be involved in the control of
expression of HERV-W elements in this tumoral context.
To assess whether the hypomethylation of HERV-W
elements in testicular cancer is restricted to these loci,
we analyzed the methylation status of three additional
HERV-W LTRs that appeared unexpressed in all the
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Figure 3. ERVWE1 locus splicing strategy in tumoral testis. (A) ERVWE1 genomic structure and transcripts. The transcription start site at the U3
promoter/R boundary of the 50 LTR is represented by an arrow, and the splice donor site (DS) and the splice acceptor sites (AS1 and AS2) leading
to the two major transcripts are indicated. ERVWE1-speciﬁc sequence signature is located by a star. The use of DS in combination with AS1 gives
rise to an 8-kb transcript. mRNA (8-kb) contains gag, pol and env regions, and does not code for protein. The use of SD in combination with AS2
gives rise to a 3.1-kb transcript. The 3.1-kb mRNA contains the env ORF exclusively, and is responsible for the production of the Syncytin-1 protein.
(B) ERVWE1 probesets. Location of the probesets designed for the detection of ERVWE1 overall transcription (envW_at) and Synyctin-1-speciﬁc
mRNA (sp.ervwe1_at) are indicated by boxes under ERVWE1 mRNAs illustration. sp.ervwe1_at is composed of probes located at the SD/SA2
junction and probes located at the locus signature (boxes with star into). Position of each probe within each probeset is detailed below, and for each
probeset, signal intensity in normal (light gray) and in related tumoral (dark gray) testis, and in placenta (black) samples are illustrated
probe-by-probe. (C) qRT-PCR quantiﬁcation of ERVWE1-spliced Syncytin-1 transcript in normal and tumoral testis. Syncytin-1-speciﬁc mRNA
(sp.ervwe1) was evaluated by qRT-PCR in four pairs of normal and tumoral related testicular samples. Expressions are normalized with the
expression of G6PD housekeeping gene having an averaged number of 1000 copies per 5ng of total RNA in 250 cells. An arbitrary cutoﬀ at
250 is indicated by a dotted line, mimicking one copy per cell. The star indicates the pair sample used in the microarray experiment.
2238 Nucleic Acids Research, 2010,Vol.38, No. 7Figure 4. Identiﬁcation of autonomous versus non-autonomous LTR activity. (A) Microarray data on U3 versus U5 activity. The dichotomic
expressions observed between the U3 and U5 regions of the LTR are represented probe-by-probe for the three identiﬁed loci with U3 and U5
parts present on the microarray. Dark gray represents tumoral-testis intensity of the probes, and light gray shows the normal-testis intensity. The
positions of all probes along the LTR are schematized below by boxes. The putative initiation site is indicated by an arrow. (B)5 0-RACE iden-
tiﬁcation of autonomous transcriptional induction for the locus HW08822. Sequence alignment of ERVWE1 50LTR, HW08822 50LTR and clones
obtained by 50 RACE are represented. The transcriptional initiation site of ERVWE1 is indicated by an arrow as well as the initiation site of
HW08822 observed in the three clones. TT1/TN1 match pair was the sample used as in microarray experiment. (C) U3- and U5-speciﬁc qRT-PCR s
in four testicular normal/tumoral pairs. Expressions of the loci identiﬁed as overexpressed in the testicular tumors are represented by dendrograms.
Expressions in LTR U3 part are in hatched gray boxes and expressions in LTR U5 part are in ﬁlled boxes. Expressions in normal RNA are in light
gray and those in tumoral RNA are in dark gray. Expressions are normalized with the expression of G6PD housekeeping gene, which had an
averaged copy number of 1000. The values for 1000 copies of G6PD gene are represented by a dotted line. The normal/tumoral sample pair used in
the microarray experiment is Testis 1 (*).
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Figure 5. U3 promoter global methylation comparison in normal versus tumoral testis. (A) Global methylation comparison in the diﬀerentially
expressed HERV-W LTR. (B) Global methylation comparison in the HERV control LTR. Comparison of CpG methylation status in normal (TN4)
and tumoral (TT4) testicular cancer sample of the U3 part of the six diﬀerentially expressed HERV-W LTRs (column A) and six HERV LTR
controls, namely, three of the HERV-W family and one of each of the HERV-E, HERV-H and HERV-FRD families (column B). All U3 parts are
represented and CpG positions are noted by gray circles; CAAT boxes are noted in light gray; and TATAA boxes in darker gray. Highly mutated
CAAT and TATAA boxes, in comparison with the reference sequence, are not represented (e.g. in the HERV-E.PTN LTR). Methylated CpG are
represented in solid circles and unmethylated CpG are in open circles, undetermined methylation status is in gray circles. Identiﬁed SNPs are
represented by gray crosses. The percentage of U3 global methylation is indicated for each LTR. For ERVWE1 locus, both the 50 LTR U3 region
and the upstream placental enhancer (TSE) are represented, and the percentage of methylation is indicated for each region.
2240 Nucleic Acids Research, 2010,Vol.38, No. 7RNA samples. One locus (HW21714) was found to be
phylogenetically related to active LTRs, whereas two
(HW35372 and HW36489) were related to inactive
LTRs as previously deﬁned [(44), S. Prudhomme,
unpublished data]. We observed two cases of methylation
behavior, that is, either a methylation decrease appeared
in the tumoral tissue or a low methylation was observed in
both the tissues (normal and tumoral) (Figure 5B).
Precisely, the global amount of methylation was over
88.5% in the normal DNA and lower than 36.4% in the
tumoral DNA for the loci HW36489 and HW35372.
Furthermore, in the tumoral DNA, up to 63.6% of
the sequences were fully unmethylated, as illustrated in
Figure 5A, whereas none was found unmethylated in the
normal counterpart. For the locus HW21714, the percent-
age of methylation observed was 30.3% and 24.2% in
normal and tumoral DNA, respectively, with a majority
of fully unmethylated sequences in both the cases. To
assess whether the testicular tumor-associated hypo-
methylation of HERV is restricted to the family W, we
analyzed the HERV loci from other families, namely,
HERV-H, HERV-E and HERV-FRD, that is, the loci
HH34532 overexpressed in colorectal cancer, and
HERV-E.PTN and ERVFRDE1 expressed in the
placenta. Again, we observed two cases of methylation
behavior, either a methylation decrease that appeared
in the tumoral tissue or a high methylation observed in
both the tissues (normal and tumoral). In the ﬁrst case
(ERVFRDE1 and HERV-H/HH34532), the amount of
methylation was over 56.9%, with no fully unmethylated
sequences in the normal tissue, and was lower than 13.8%
in the tumoral tissue, with 80–100% of fully unmethylated
sequences. In the second case (HERV-E.PTN), the
amount of methylation was stable and over 88.9% in
both the tissues.
Altogether, these results suggest that the methylation
deregulation in this tumoral context concerns neither the
HERVs as a whole nor the diﬀerentially expressed
HERV-W loci alone.
DISCUSSION
HERV transcriptional activities have been evidenced
in several physiological and pathological contexts.
However, the multicopy nature of these repeated
elements leads to substantial diﬃculties to identify which
locus (loci) is (are) related to the observed activities, and
whether such locus (loci) expression resulted from
self-activation or readthrough. As a consequence, this
often limits the range of the results and the determination
of the physiological or pathological contribution that
could have one or several HERV loci within a family.
Thus, several research groups are currently developing
speciﬁc tools to analyze HERV transcriptome. This
study is the ﬁrst attempt to elaborate a high-density
microarray designed to speciﬁcally detect the activity of
HERV individual sequences.
First, the probes were designed following the most
simple/basic criteria excluding all other criteria (i.e.
uniqueness), indicating that theoretically, each single
sequence belonging to one locus and presenting at least
one mutation, as referred to all other loci, is selected onto
the microarray. In the case of HERV families, with a
divergence between the loci below 20%, these criteria
were relatively stringent, leading to several regions
without any unique probe. In addition, despite being
unique, a probe dedicated to a particular locus may not
be speciﬁc under the hybridization conditions on the chip.
Second, owing to the limited number of features on the
chip and the redundancy of information about the neigh-
boring overlapping probes, a probe selection process was
developed. The choice between the neighboring probes
was realized to preferentially select the probes with the
informative mismatches located in their center part.
These criteria of selection, which was preferred to the
probe’s quality or probeset composition, as theoretically
favoring speciﬁcity, led to two main adverse eﬀects: (i) the
exclusion of good quality probes and (ii) the creation of
poorly representative probesets with few probes. An
optimized solution would take into account all three
parameters in the selection algorithm. Overall, this
process of selection may explain the observed cross-
reactivities, and thus, the diﬃculty to trace back the
original loci, although clear diﬀerential expression may
be attributed to the given probesets. In addition,
exhaustivity and redundancy problems of GenBank
release 128, when compared with the present assembled
version of the human genome (release 171), in particular
for repetitive elements, suggest a bias in the data used for
this chip design. Hence, with respect to the number of
identiﬁed active loci, this version of the microarray
seems less eﬃcient than other global approaches such as
PCR coupled with sequencing (30) or GREM technique
using PCR and terminating at the sequencing step (31).
Conversely, the use of several probesets onto a locus
provided more information concerning transcriptional
regulation, than the PCR-based process did when tar-
geting a single internal domain (29). Signals from indepen-
dent probesets for U3 and U5 regions may reﬂect a
promoter activity (U3 negative, U5 positive), a poly-
adenylation role (U3 positive, U5 negative), or a
readthrough phenomena (U3 and U5 positive). Thus,
the over-representation of the U5 regions for the 100
most diﬀerentially expressed LTR loci suggests that acti-
vation of HERVs, predominantly found in tumors, is
essentially autonomous. More precisely, U3 negative
versus U5 positive signals for HW08822, HW13386 and
HW33438 loci, overexpressed in one TT sample, suggest
an autonomous transcription, controlled by their respec-
tive U3 promoter. Nevertheless, we cannot formally
exclude that some of the U5 observed activations are
related to HERV pseudogenes lacking U3 promoter
(45). In addition, the detection of high or signiﬁcant
signal intensities (i) in the placenta and TT for
sp.ervwe1_at probeset targeting the Syncytin-1-speciﬁc
splice junction and (ii) in testicular tumors for probesets
detecting HML-2 double-spliced transcripts, np9 and
cORF, indicate that the use of such microarray technology
makes it possible to identify tissue-associated HERV
splicing strategy, as previously described for conventional
genes (46).
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samples and probes onto the chip, the ampliﬁcation
process employed is theoretically unbiased. Because of
the use of random primers, this concerns the relative
ampliﬁcation eﬃciency of the 50 and 30 ends of mRNAs
and the equivalency of ampliﬁcation of distant versus
closely related sequences, as opposed to gag–pol
region-based PCR methods (30) or restriction enzyme
coupled with the PCR-based method (31). This advantage
is clearly illustrated by the eﬃcient detection of 50 terminal
U5 regions, notably for the 100 most diﬀerentially
expressed LTR loci that consist of both 50 long proviral
LTRs and short solo LTR. This is also illustrated by the
simultaneous analysis of HERV-W, HML-2, HERV-E
and HERV-H families, as primarily limited to the
HML-2 family in other methods (30,32). Moreover, the
relative abundance of all HERVs mRNA has been theo-
retically preserved using linear transcriptional ampliﬁca-
tion. The use of triplicates demonstrated remarkable
robustness of the overall process (e.g. conserving relative
abundance of distinct targets). The median-intensities cor-
relation among the triplicates varied from 0.911 to 0.991
among all the samples (median=0.979), highlighting the
linearity of the relationship and the infrequency of the
outliers. Moreover, by using raw data for each probe
with a signal higher than 70, the median CV ranged
from 11.3 to 24.7% (median 15.3), which is similar to
the PCR-based target ampliﬁcation coupled with hybrid-
ization onto a solid surface (25). In addition, the overall
process was found to be less prone to ex vivo recombina-
tion, as observed with RT coupled with PCR exponential
process (29).
Although the observed speciﬁcity problems limit the
actual extent of the interpretable results from this
version of the chip, several published data indicate that
the microarray is reliable enough to reveal previously
unidentiﬁed events. Yet, as a general concern regarding
the biological signiﬁcance of diﬀerential expression,
it should be noted that further investigations will be
required, as so-called normal tissue adjacent to the
tumor is not necessarily the most appropriate control
since (i) the cancer precursor cell is not necessarily neigh-
boring the tumor depending on the type of cancer and
conversely (ii) the adjacent tissue may represent a pre-
cancerous state. Thus, all the samples evaluated (with
the exception of placenta and ovary samples) with the
chip technology were similar to those previously
analyzed with a quantitative multiplex degenerate PCR
coupled with an oligosorbent assay (MD-PCR OLISA),
based on the relative conservation of the pol genes and by
targeting nine families (25,26). The initial observations
focused on the signiﬁcant signals derived from the pro-
besets of ERVWE1, ERVFRDE1 and ERV3/HERV-R
loci, which are known to be highly expressed in the
placenta (34,47–49). It can be noted that the p-value for
the envR probeset diﬀerential intensity in the placenta was
not as signiﬁcant as that for ERVWE1 and HERV-FRD
probesets, in accordance with the published envR expres-
sion in several other normal tissues, as opposed to
ERVWE1 and ERVFRDE1 (18). As ERVWE1 probesets
proved useful in analyzing placenta mRNA, the absence
of signals in the breast tumoral sample may reﬂect a
speciﬁc behavior of this particular sample, with respect
to the report of ERVWE1 activation in 30% of breast
cancer samples (7). Conversely, the absence of HERV-W
family overexpression in the ovarian cancer sample, as
previously described (50), may be owing to the lack of
exhaustiveness of the HERV-W family onto the chip.
The identiﬁcation of several HERV-W loci in TT corre-
lates with the initial observation of the overexpression of
the HERV-W family in the same match-pair sample (25).
The overexpression of at least ﬁve loci was conﬁrmed by
qRT-PCR on three additional seminomal samples. Thus,
these HERV-W loci represent novel candidate cancer
markers that need to be validated on larger sample panels.
However, we did not observe the previously described
overexpressions of HERV-K(HML-2) types 1 and 2 in
breast cancer (51–53). HERV-K(HML-2) expression in
normal and tumoral breast samples is highly variable,
and similar levels of expression are often found between
the tumor and the adjacent normal breast tissues.
However, the breast sample pair was previously investi-
gated using MD-PCR OLISA that displayed more than
250-fold increase in HML-2 pol transcribed sequences
(25). Although there is no deﬁnite explanation, the
previously observed overexpressions may have resulted
from the accumulation of a faint transcription of diﬀerent
and numerous loci, undetectable by the overall chip
process based on statistical signiﬁcance. Alternatively,
because of the sequence uniqueness criterion used to
design the probes, the HERV-K(HML-2) family may
not be represented exhaustively on the microarray, as sug-
gested earlier for the HERV-W family. Nevertheless,
HML-2 50LTR U5 regions, gag and env regions, as well
as np9 and cORF probesets’ diﬀerential expressions,
were found in the testicular tumor, in accordance with
several reports on the presence of these HML-2 transcripts
in testicular tumors (37). Moreover, the HML-2 over-
expression previously observed in lung tumor sample
(25) was limited to type 2 elements, as np9 but not Rec
expression was detected.
The high intensity observed in HERV-H 50LTR U5
regions and HERV-H envh3 gene probesets is in accor-
dance with the report on HERV-H activity in colon tumor
(25,27,54).
Finally, the diﬀerential expression presented by a
probeset cluster from the HERV-E4.1 family in prostate,
as previously described (21,25), and/or ovary and/or
uterus tumors illustrates the heterogeneity of the transcrip-
tional regulation process among the elements of this
family. The fact that most of the corresponding probesets
derived mainly from solo LTR (83%) may explain why
such an expression have not been observed in tumoral
uterus using the pol-based MD-PCR OLISA system
(26). More precisely, these results putatively illustrate the
existence of at least ﬁve HERV-E subgroups, namely,
(i) overexpressed in prostate–ovary–uterus tumors; (ii)
in prostate–ovary tumors; (iii) in prostate tumors only;
(iv) down-regulated in tumoral uterus; and (v) highly
expressed in both prostate and uterus tissues, irrespec-
tively of their tumoral status. A preliminary phylogenetic
analysis shows that all these elements are away from the
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E.PTN, HERV-E.EBR and HERV-E.APOC1 loci (10,55).
Analyses of the transcriptional regulation features of
the several HERV-W loci, primarily identiﬁed as
overexpressed in seminoma by the microarray whole pro-
cedure and conﬁrmed using dedicated methods, are of
general interest concerning the mechanisms leading to
HERV contribution to the biological activities, essentially
in human pathology.
First, a post-transcriptional alteration was illustrated by
the ERVWE1 locus behavior in the tumoral section of
four patients, evidenced using the microarray on one
patient and conﬁrmed by qRT-PCR on four samples. It
has been originally described that the ERVWE1 locus can
produce two major large-splice transcripts, a non-coding
8-kb mRNA and the Syncytin-1-related 3.1-kb mRNA,
and a smaller largely-spliced 1.5-kb mRNA, at least in
placenta (34). The 8-kb transcript was detectable in three
out of four normal testicular samples, as formerly
described (56). Interestingly, in the four seminomas, the
overexpression of ERVWE1 was associated with an induc-
tion of the 3.1-kb mRNA production. However, whether
the appearance of this spliced form reﬂects an overall
increase in the transcription of the locus or results from
a modiﬁcation of the pool of cellular factors aﬀecting the
splicing strategy, needs further investigations. Most
intriguingly, the presence of ERVWE1 3.1-kb transcript
is presumed to lead to the production of the Syncytin-1
protein in seminoma, as observed quite frequently in other
cancers (7–9).
Second, and of more general interest, the regulation of
LTR expression in tumoral tissues was addressed by
analyzing the six identiﬁed HERV-W elements over-
expressed in seminoma. On one hand, it remains generally
unclear whether transcribed HERV mRNA are LTR-
promoted, LTR-polyadenylated, or readthrough products
initiated from the neighboring conventional (non-
retroviral) promoters. On the other hand, transcriptional
re-activation in cancer could be attributable to several
mechanisms, such as tumor-associated changes in the
transcription factors (putatively altering transcription
initiation), alterations in chromatin-histone code, or mod-
iﬁcations in DNA methylation.
Using U3- and U5-speciﬁc primer pairs in real-time
PCR comparative assays, we conﬁrmed that all six
HERV-W-loci-derived mRNA were U3-promoted. This
mode of control of expression was exclusive and preserved
for HW08822, HW13386 and HW38223 and ERVWE1/
HW28073 elements in all patients. Coupled with this
U3-driven expression, a classical 50-R-dependent initiation
of transcription has been suggested by the RACE analysis
of the HW08822 locus in tumoral tissue. It is similar to the
one identiﬁed with the domesticated ERVWE1 locus (34),
and is diﬀerent from the 30-R-transcription start point
of human-speciﬁc HML-2 elements (57). Nevertheless,
whether this reﬂects a particular functionality or is a sig-
nature of the HERV-W family remains to be deciphered.
U3-promoted transcription was also found to be a major
but not an exclusive phenomenon for the HW33438 locus
that additionally exhibited a low transcription of the U3
region. This observation may be owing to the generation
of two independent transcripts, with the minor transcript
resulting from an upstream initiation of transcription in
the promoter domain (data not shown), possibly owing to
an altered/ineﬃcient TATAA box (58). Such a generation
of two independent transcripts for the HW22795 locus,
each containing either the U3 or the U5 LTR region,
was also observed in two out of four patients. This kind
of proﬁle was previously reported by Vinogradova et al.
(59) for HERV-K LTRs in the T-cell leukemia Jurkat
cell line following heat-shock, as well as in seminoma.
An overrepresentation of the U5 signal was found to
indicate that the main mechanism is the U3-promoted
sense-oriented transcription mechanism. Strikingly, such
U3-containing mRNA was also detected in two other
testis tumoral samples that lacked U5 expression. U3
expression of both HW22795 and HW33438 LTR may
either reﬂect a transcriptional terminator function
(U3-R-polyA) or an antisense transcript, as HERV-W
LTR was shown to possess a bi-directional promoter
activity (60). Alternatively, such features may reﬂect
the heterogeneity of the tumor, leading to a combina-
tion of transcription factors targeting hetero-
geneously and independently in the subpopulation,
HW22795 and HW33438 LTRs. In such situation, expres-
sion of HW08822, HW13386 and HW38223, as well
as ERVWE1/HW28073 LTRs would not be aﬀected
by heterogeneity. Although speculative, it is worth
noting that the activation of these HERVs may alter
the expression of the adjacent genes (Supplementary
Table S3); for instance, retroviral-induced production
of GATAD1-interfering antisense transcripts owing to
ERVWE1 reactivation (tail-to-tail elements) as previously
described (12), and promoter competition between
HW33438 and ADAMTS1 owing to the LTR-observed
antisense activity (head-to-head elements), as described
earlier (61).
Bisulﬁte-PCR sequencing of the six reactivated
HERV-W loci initially showed that their promoter
domains were highly methylated in the normal adjacent
tissue, which is in agreement with the methylation-
dependent silencing of the HERVs in most somatic cells
(15–17). Conversely, in testicular cancer, a strong DNA
hypomethylation of these activated LTR 50 U3 promoter
domains was observed. Nevertheless, analyses of three
additional HERV-W loci that were not expressed
showed that hypomethylation was tumor-associated in
two of them and was an intrinsic attribute in one of
them. In DNA isolated from a true normal testis tissue
(fatal accident), CpG methylation of HW8822 active LTR
and HW35372 inactive LTR were similar to the one
observed in adjacent tissue (data not shown). Thus,
analyses of this short collection of nine HERV-W LTRs
suggest that the HERV-W intrafamily hypomethylation
seems homogeneous in the tumoral section, irrespective
of the transcriptional activation of the LTR copy. First,
it is noticeable that LTR activity cannot be correlated with
the age of the elements, as all active elements belong to the
most recent HERV-W subfamily 3 and inactive LTR
belongs both to the subfamily 3 and 2 (62). Thus, the dif-
ference in HERV-W elements’ transcriptional activity
could be explained by the diﬀerences in the ability of the
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Second, taken as a whole, the median of methylation
of those nine HERV LTRs drops from 91% in normal
testis to 21% in the tumor, which is in agreement with
methylation deregulations observed in seminoma, with
the residual level of LTR methylation appearing higher
than CpG methylation measured by immunohisto-
chemistry (63). This suggests that demethylation in
cancer does not equally aﬀect all the components of the
genome. More precisely, this suggests that the observed
(de)methylation relies upon a (sub)family-dependent tar-
geting, putatively based on sequence homology, which
would have a direct impact on the risk and frequency of
ectopic pairing and recombination among the homolo-
gous elements. It should be noted that seminoma was
proposed to evolve from primordial germ cells (PGCs)
(63,64), in which genome methylation is mostly erased
before being reprogrammed along the spermatogenesis
pathway (65). Therefore the observed homogeneous
hypomethylation of the HERV-W LTRs in seminoma
could at least partly reﬂect a physiological methylation
state corresponding to PGCs. However, we cannot
exclude that some HERV-W elements remain hyper-
methylated as proposed for malignant ovarian tissue,
where a global hypomethylation of the HERV-W family
was reported (50). Overall, the control of the (de)methyla-
tion process appears to be diﬀerent in this pathological
situation than that observed in the placenta physiological
context, where (hypo)methylation of HERV sequences
appeared limited to the functional domesticated elements
(16,17). As opposed to the HERV-W elements, prototype
LTRs of HERV-E, HERV-H and HERV-FRD families
showed extremely diﬀerent levels of methylation in the
tumor. In the context of the PGCs scheme, this would
indicate a distinct and apparently sequence-dependant
remethylation process of HERV families (or at least par-
ticular elements) during spermatogenesis. Interestingly,
the HERV-E LTR that remains highly methylated in the
tumor is the element whose environment comprises scanty
repeated elements and abundant genes (Supplementary
Table S3). Nevertheless, environment is not the only
factor inﬂuencing methylation, as the HW21714 LTR
that is eﬀectively hypomethylated in normal tissue is
located within a gene-rich environment (Supplementary
Table S3). Furthermore, the domesticated ERVFRDE1
locus, located in a region rich in repeated elements and
genes (Supplementary Table S3), exhibits an unusually
low level of methylation in the normal tissue, including
almost completely unmethylated copies, when compared
with the other HERV elements. Taken together, these
observations suggest a multifactor process modulating
methylation of HERVs in cancer, including preferably
sequence (family), then chromosomal environment and
possibly locus domestication/function. This is in agree-
ment with the recent data showing that 5–8% of repetitive
elements demonstrate cancer-related DNA methylation
alteration, and that the loss of DNA methylation is
most pronounced for certain members of the HERV
families (66).
CONCLUDING REMARKS
This study is the ﬁrst attempt to identify individual locus
HERV expression using high density microarray format.
When compared with the sequencing-based methods, the
clearly identiﬁed advantages of the microarray format to
decipher HERV transcriptome consist of (i) simultaneous
detection of the diﬀerential activity of several, if not all,
HERV families and (ii) simultaneous but independent
examination of the diﬀerent regions for each individual
locus, including U3 and U5 parts of LTR, internal gag
or env regions, and spliced junctions as well, without
any a priori knowledge related to the functionality of the
HERV sequence. Although the presented results represent
the proof of concept of such method, the current version
of the chip is far from this ideal situation. The microarray
is currently being upgraded by improving the probes’
design and, in parallel, by increasing the exhaustiveness
of HERV families. We are thus moving from the initial
chosen criteria, uniqueness, to a second-generation one,
namely, speciﬁcity. In addition, curated and assembled
genome-based database, when compared with the release
used for this chip version, may facilitate such a design.
This ﬁrst-generation HERV microarray allows for the
conﬁrmation of several previous independent reports on
HERV expression in diﬀerent contexts. Moreover, modi-
ﬁcations of ERVWE1 splicing strategy in testicular tumor
suggest that the implication of Syncytin-1 envelope has
to be further investigated. Indeed, owing to its fuso-
genic, diﬀerentiation and anti-apoptotic properties, it is
presumed to have a role of an oncogene or tumor suppres-
sor in (testicular) cancer. Finally, the tumor-associated
hypomethylation of the U3 LTR part of various HERV
loci, whether reactivated or not, implies that alteration in
methylation is a critical step toward HERV activation in
cancers, and that the involvement of DNA methyltrans-
ferases in HERV targeting and regulation alterations in
cancers should be addressed precisely.
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